ATE495750T1 - Sulfatide zur behandlung von autoimmunkrankheiten - Google Patents

Sulfatide zur behandlung von autoimmunkrankheiten

Info

Publication number
ATE495750T1
ATE495750T1 AT06816075T AT06816075T ATE495750T1 AT E495750 T1 ATE495750 T1 AT E495750T1 AT 06816075 T AT06816075 T AT 06816075T AT 06816075 T AT06816075 T AT 06816075T AT E495750 T1 ATE495750 T1 AT E495750T1
Authority
AT
Austria
Prior art keywords
sulfatides
treatment
autoimmune
immune related
autoimmune diseases
Prior art date
Application number
AT06816075T
Other languages
English (en)
Inventor
Vipin Chaturvedi
Original Assignee
Torrey Pines Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrey Pines Inst filed Critical Torrey Pines Inst
Application granted granted Critical
Publication of ATE495750T1 publication Critical patent/ATE495750T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT06816075T 2005-09-29 2006-09-28 Sulfatide zur behandlung von autoimmunkrankheiten ATE495750T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72218405P 2005-09-29 2005-09-29
PCT/US2006/038539 WO2007038785A1 (en) 2005-09-29 2006-09-28 Sulfatides for treatment of autoimmune disorders

Publications (1)

Publication Number Publication Date
ATE495750T1 true ATE495750T1 (de) 2011-02-15

Family

ID=37532920

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06816075T ATE495750T1 (de) 2005-09-29 2006-09-28 Sulfatide zur behandlung von autoimmunkrankheiten

Country Status (8)

Country Link
US (1) US8044029B2 (de)
EP (1) EP1940418B1 (de)
JP (1) JP2009510124A (de)
AT (1) ATE495750T1 (de)
CA (1) CA2623946A1 (de)
DE (1) DE602006019759D1 (de)
ES (1) ES2360235T3 (de)
WO (1) WO2007038785A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2040541B1 (de) * 2006-06-30 2016-03-23 The Scripps Research Institute Hilfsstoffe und verwendungsverfahren
AU2012272642B2 (en) * 2011-06-24 2017-09-07 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
ES2860823T3 (es) 2014-12-09 2021-10-05 Gri Bio Inc Prevención y tratamiento de afecciones inflamatorias
US20240277740A1 (en) * 2020-05-16 2024-08-22 Viratides, Llc Treatment of known and unknown viral infection with lipid agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674690A (en) * 1992-10-08 1997-10-07 New York University Methods of diagnosis, monitoring and staging of various conditions using IgG antibodies against hydroxy-fatty acid containing sulfatide
CA2142153A1 (en) * 1994-03-04 1995-09-05 Jacques Banville Sulfated .beta.-glycolipid derivatives as cell adhesion inhibitors
DE69526228T2 (de) * 1994-07-27 2002-10-24 Genzyme Ltd., Haverhill Regioselektive sulfatierung
US5486536A (en) * 1994-08-15 1996-01-23 The Regents Of The University Of Michigan Sulfatides as anti-inflammatory compounds
JPH08109134A (ja) 1994-10-11 1996-04-30 Sanwa Kagaku Kenkyusho Co Ltd 細胞変成抑制並びに臓器毒性軽減剤
SE9601817D0 (sv) * 1996-05-13 1996-05-13 Karsten Buschard Novel glycolipid complexex and their uses
US7534434B2 (en) * 2004-12-28 2009-05-19 The Rockefeller University Glycolipids and analogues thereof as antigens for NK T cells

Also Published As

Publication number Publication date
ES2360235T3 (es) 2011-06-02
WO2007038785A1 (en) 2007-04-05
US8044029B2 (en) 2011-10-25
EP1940418B1 (de) 2011-01-19
DE602006019759D1 (de) 2011-03-03
EP1940418A1 (de) 2008-07-09
US20070087979A1 (en) 2007-04-19
CA2623946A1 (en) 2007-04-05
JP2009510124A (ja) 2009-03-12

Similar Documents

Publication Publication Date Title
WO2007136518A3 (en) Treatment of autoimmune disorders
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CY1111478T1 (el) Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης
PH12014500239A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CY1111359T1 (el) Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
TNSN07191A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
ATE552837T1 (de) Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen
WO2007053661A3 (en) Uses of anti-cd40 antibodies
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
ATE470151T1 (de) Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
MX2023002350A (es) Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?
EA200702534A1 (ru) Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2)
EA200601580A1 (ru) Пептид, стимулирующий регенерацию нейронов центральной нервной системы, фармацевтическая композиция на его основе и способ ее применения

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties